Zyprexa Tablet, Orally Disintegrating
NDC Package 61269-652-35
Package Information
Zyprexa (olanzapine) tablets is olanzapine is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by H2-pharma Llc, this product is identified by NDC 61269-652 and is authorized under FDA application NDA021086.
Identification & Billing
- RxCUI: 153046 - ZyPREXA 5 MG Oral Tablet
- RxCUI: 153046 - olanzapine 5 MG Oral Tablet [Zyprexa]
- RxCUI: 153046 - Zyprexa 5 MG Oral Tablet
- RxCUI: 153047 - ZyPREXA 7.5 MG Oral Tablet
- RxCUI: 153047 - olanzapine 7.5 MG Oral Tablet [Zyprexa]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61269 - H2-pharma Llc
- 61269-652 - Zyprexa
- 61269-652-35 - 30 DOSE PACK in 1 CARTON / 1 BLISTER PACK in 1 DOSE PACK (61269-652-01) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
- 61269-652 - Zyprexa
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61269-652-35 identifies a specific commercial package of 30 dose pack in 1 carton / 1 blister pack in 1 dose pack (61269-652-01) / 1 tablet, orally disintegrating in 1 blister pack of Zyprexa Zydis, a human prescription drug labeled by H2-pharma Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet, orally disintegrating is formulated for oral use and contains olanzapine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by H2-pharma Llc on September 01, 2001. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Olanzapine is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medication to treat depression. This medication can help to decrease hallucinations and help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Olanzapine belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain. Talk to the doctor about the risks and benefits of treatment (especially when used by teenagers). See also Precautions section.
How is this H2-pharma Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61269065235. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.